Which company produces Repotrectinib?

Repotrectinib (Repotrectinib) is a new generation of oral small molecule tyrosine kinase inhibitors originally developed by TurningPoint Therapeutics. The company focuses on precision tumor treatment and uses its innovative strategies to accelerate drug progress in the field of tumor treatment. In 2022, Bristol Myers Squibb (BMS), a subsidiary of Johnson & Johnson, completed the acquisition of TurningPoint Therapeutics and added this breakthrough drug to its oncology drug portfolio. According to official news from Bristol-Myers Squibb, the company has been fully responsible for the subsequent development, global promotion and launch strategy of Ripotinib since then.

Ripotinib precisely targets the ROS1 fusion protein and NTRK (neurotrophic tyrosine receptor kinase) fusion variants, which play a driving role in a variety of solid tumors. Compared with previous generation TKIs, it has a stronger ability to cross the blood-brain barrier and inhibit drug-resistant mutations. These advantages make it significantly valuable in the treatment of ROS1-positive non-small cell lung cancer (NSCLC) and NTRK-positive solid tumors. In November 2023, the U.S. Food and Drug Administration (FDA) approved Ripotinib for the treatment of locally advanced or metastatic ROS1-positive NSCLC, and further expanded to the NTRK fusion-positive solid tumor population in June 2024, becoming the first FDA-approved TKI drug to treat these tumors.

TurningPoint Therapeutics' initial TRIDENT-1 multicenter study, covering ROS1- and NTRK-driven NSCLC and other solid tumors, demonstrated that rapatinib demonstrated high response rates and durable responses in both prior TKI-experienced and treatment-naïve patients. After the acquisition, BMS leveraged its mature global oncology drug launch and patient support network to promote the launch of Ripotinib in multiple countries and regions, including the United States, the European Union, China and other regions. After 2025, with the approval of more countries and the disclosure of long-term real-world research results, its position in the field of precision therapy is expected to be increasingly consolidated.

Reference materials:https://www.drugs.com/mtm/repotrectinib.html